Tumor Necrosis Factor Blocker [EPC]

767612 reported adverse events

Drugs of this class: ETANERCEPT INFLIXIMAB GOLIMUMAB CERTOLIZUMAB PEGOL INFLIXIMAB-AXXQ INFLIXIMAB-DYYB

These side effects are most commonly reported by patients taking drugs of the Tumor Necrosis Factor Blocker [EPC] class:

#	Side effect	Count
0	DRUG INEFFECTIVE	89752
1	INJECTION SITE PAIN	57278
2	ARTHRALGIA	49733
3	PAIN	44922
4	RHEUMATOID ARTHRITIS	44447
5	INJECTION SITE ERYTHEMA	41353
6	OFF LABEL USE	39948
7	FATIGUE	33371
8	HEADACHE	27686
9	PSORIASIS	27470

See all common reactions for Tumor Necrosis Factor Blocker [EPC]

Drugs of the Tumor Necrosis Factor Blocker [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	INJECTION SITE RECALL REACTION	481	0.9776
1	HUMAN ANTICHIMERIC ANTIBODY POSITIVE	284	0.9759
2	ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE	2404	0.9307
3	SWOLLEN JOINT COUNT INCREASED	451	0.8826
4	RHEUMATOID FACTOR POSITIVE	2229	0.8677
5	RHEUMATIC FEVER	580	0.8657
6	RED BLOOD CELL SEDIMENTATION RATE ABNORMAL	1514	0.8646
7	PEMPHIGUS	4576	0.8525
8	C-REACTIVE PROTEIN ABNORMAL	2387	0.8037
9	HAND DEFORMITY	4764	0.7630

See all enriched reactions for Tumor Necrosis Factor Blocker [EPC]